

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Quick Heal Technologies Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose.





Agenda

Q4FY20 & FY20 Earnings Highlights

Company Overview

Industry Overview

ဂ္ဂို ဂို ဂို The Quick Heal Advantage

Q4FY20 & FY20 Earnings




Q4FY20 & FY20 EARNINGS HIGHLIGHTS



Q4FY20 & FY20 Earnings Highlights

Our FY 2020 financial performance was weakened due to slowdown in the economy which lead to credit crunch among MSME coupled with headwinds at our channel partners. The impact further worsened by COVID-19 pandemic which lead to lockdown in entire country





Company at a glance



Vision

To be the trusted global leader in securing the digital world


Mission

Secure our customers by providing innovative, most preferred and valued security solutions, services and knowledge

Protect information and interactions on all types of networks, devices & things globally

Build a healthy business and organization

Over 25 years of simplifying security






- India's first listed cybersecurity
 products company
- A "Make in India" product configured to secure countries, cities and companies
- Quick Heal undisputed leader in the retail segment
- Seqrite making inroads in the SMB & enterprise segment
- Quick Heal Security Labs a team of highly efficient security researchers, analysts and engineers leverages a combination of Al, cloud and patented technologies to deliver timely and advanced protection
- Solutions to secure across platforms

Shareholder information

Shareholding structure – 31st March 2020



Shareholder Information (as on 31st Mar 2020)

NSE Ticker	QUICKHEAL
BSE Ticker	539678
Market Cap (₹ mln)	5,217
% Free-float	27.17%
Free-float market cap (₹ mln)	1,417
Total Debt (₹ mln)	
Cash & Cash Equivalents (₹ mln)	3,877
Enterprise Value (₹ mln)	1,340
Shares Outstanding	6,42,03,618
3M ADTV (Shares)	2,34,620
3M ADTV (₹ mln)	28.0
Industry	IT Software Products



INDUSTRY OVERVIEW

REARDING

OF NUMBER

11 31

eff 84

state is such that is been in a such that is such in the such in the such is s

and and have seen the last the last and the

T II 11


THE REPORT OF

JE II H

TE


-

2020 Cyber threat landscape shows that...




Source: Quick Heal Annual Threat Report 2020


...cyber-attacks continue to grow in scale and sophistication...



...together with rapid growth in India's digital adoption...




... is expected to increase Cybersecurity spending in India



Cybersecurity market in India is expected to grow at ~16% CAGR between 2019 to 2022 and become a \$3 bln market with security product market estimated to grow at ~17% to become \$1.6 bln market. Quick Heal is well placed to capitalise on this opportunity.

Global cybersecurity market along with cyber threat predictions for 2020








THE QUICK HEAL ADVANTAGE

Quick Heal is well positioned to leverage its strengths to capture the future opportunities



Strong threat detection and prevention capabilities...



Powers SIGNATURE-LESS and SIGNATURE-BASED detections

Our best and the most innovative malware hunting engine brings together the best of the best!



Par De

Patented Behavior Detection System






Cloud Based Deep Learning Module

...with State-of-the-Art **Research & Development** leading to Innovations

25+ years of experience coupled with vast distribution network across India has helped us understand security market and issues faced by millions of users in depth which has led to consistent introduction of innovative products and solutions for our customers

Product **Security Labs Management Team** Detect and analyze Ensures that we build threat vectors across the right products for the globe and provide the right markets at **F** advanced protection the right time to customers Incidence Product **Response Team** Development Team Ensures customers are unaffected by Designing & building critical attacks/ cutting edge outages by products & solutions responding promptly **Research & Development** 一 一 一 一 一 Internet of Things (IOT) **Security Team** Quality Creating solutions to **Assurance Team** ensure all your connected devices and creating industry are secure for quality

Product Portfolio – Enterprise & Government



21

Product Portfolio – Home, SOHO & Mobile



Robust sales & distribution network in India

Complimentary support from Quick Heal Zonal and regional sales team to engage and support

Landscape across Class B &C towns

channel

Growing presence of T1 distributors across B&C towns. Strong network of T2 resellers - across Class B and Class

Sales Execution Robust pan India coverage


Metro Sales Coverage

Strong presence across the top metros in India. Coverage through T1 distributors and T2 resellers

Presence in Class A towns

Strong distribution across Class A towns backed by T2 resellers

QUICK HEAL Global Presence



24



Committed to deliver exceptional **Customer experience**

Multi-lingual end user support in English, Hindi and several other major regional Indian languages

2 Availability of data sheets, product videos and manuals on website for providing information on technical specifications, installation guide, upgrade mechanisms

Release of various articles, technical papers, quarterly threat reports and conducting webinars in the area of security software



Experienced Board of Directors



Dr. Kailash Katkar MD & CEO

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution



Dr. Sanjay Katkar Joint MD & CTO

Spearheads the creation and subsequent development of the core product technology



Mr. Shailesh Lakhani Non-Executive Director

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director



Mr. Amitabha Mukhopadhyay Independent Director

Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax



Ms. Priti Rao Independent Director

Has 20+ years of diverse experience in building and delivering a range of IT services for customers Located across five continents



Mr. Mehul Savla Independent Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI



Ms. Apurva Joshi Independent Director

Certified bank forensic accounting professional and anti – money laundering expert

...along with strong Management...



Dr. Sanjay Katkar Joint MD & CTO

Co-founder of the Company

Leads the global technology strategy & is responsible for the core research & development of the products.

Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums.

Holds Master's degree in Computer Science from the University of Pune. Dr. Kailash Katkar MD & CEO

Co-founder of the Company

Has been the driving force in growing Quick Heal Technologies since it's inception.

A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy. Mr. Nitin Kulkarni *CFO*

25+ years of experience in managing different aspects of finance in IT and Manufacturing Industry.

Previously held leadership positions at Tech Mahindra, KPIT, Atlas Copco India and Persistent Systems.

A member of the Institute of Chartered Accountants of India.

...and seasoned Leadership team



Ms. Reetu Raina Chief Human Resources Officer

Responsible for driving HR and steering the company's people operations, culture and recruitment initiatives.

Ms. Raina holds extensive industry experience and has worked across sectors such as Telecom, BFSI, and IT.

She has held leadership roles with domain-leading brands such as TATA, HDFC Bank, and Amdocs. She was the Head of HR at Sterlite Technologies.



Mr. Deepak Mishra Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand.

Has extensive exposure in sales and distribution, channel management, and building a robust distribution to drive productivity and profitability.

20 years of experience in FMCG, Beverages, Telecom and IT Industries.



Mr. Kuldeep Raina Head, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level.

Passionate technocrat with a rich flare for sales and ability to drive targets in dynamic business environment.

20 years of diverse sales experience including leadership roles in cybersecurity companies.



Mr. Bijoe George Head, Global Marketing

Marketing strategist with over two decades of rich data-driven, integrated marketing experience.

Leading marketing transformation to deliver strategic value. Has extensive experience working on technology brands that include Cisco, HPE, Infosys, Citrix to name a few.

Bijoe loves the interplay between strategy, technology & creative while delivering results, big ideas and big wins.

Strong brand recognition...





...backed by Certifications, Patents and...



Patented Technologies

USPTO 10,387,649

Signatureless Behaviour-based Detection Technology

USPTO 10,311,234 Anti-Ransomware technology

USPTO 8,973,136

System and method for protecting computer systems from malware attacks

USPTO 8,914,908

A completely automated computer implemented system and method for piracy control based on update requests

USPTO 8,347,389

System for protecting devices against virus attacks

USPTO 7,945,955

Virus detection in mobile devices having insufficient resources to execute virus detection software

Our marquee customers



Securing the future through our community initiatives



Lives directly impacted since 2016



Cybersecurity

- Cybersecurity Awareness
- Securing Futures through secured programming



20,000+ Lives directly impacted since 2016



Education

- Life Skills Education
- Shaalangan Counselling Centre



2,500+ Lives impacted since 2016



Eradicating Extreme Hunger & Poverty

Project Disha works with Paud's Katkari Tribe



Quick Heal Academy to drive the next generation of cyber security experts



Popular Courses

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- ✓ Security Operations Centre (SOC)
- ✓ Electronic Crime Scene Investigation

Offerings



Academy Partners

Savitribai Phule Pune University

Designed 'M-Tech in Information Security' Program for Savitribai Phule Pune University

Quantum University

U

Quantum

a

CHITKARA

UNIVERSITY

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security

Gujarat Forensic Sciences University

MoU with Gujarat Forensic Sciences University during Vibrant Gujarat 2017

Maharashtra Cosmopolitan Education Society

The society runs 30 institutes from its ultra modern campaigns located in Maharashtra

Chitkara University

MoU with Chitkara University Introduced an additional stream in Cyber Security for the four-year Undergraduate program

Deen Dayal Upadhyaya College

MoU with Deen Dayal Upadhyaya College, a constituent college of the University of Delhi

Disclaimer: Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose



Quick Heal Security Simplified


Q4FY20 & FY20 EARNINGS

Q4FY20 - Consolidated Performance Highlights




Revenue was down 25.3% in Q4FY20 due to sudden lockdown in India which affected our distribution of products to our channel partners


FY20 - Consolidated Performance Highlights



Q4FY20 impact of COVID-19 impacted our yearly sales as historically Q4 is always our strong quarter in terms of revenue

Q4 & FY20 Segment Performance - Revenue break-up






Based on net revenues before adjusting for sales incentives

Q4FY20 Figures are low due to **COVID-19** impact

(₹ mln)

Q4 & FY20 Segment performance – Licenses Sold Analysis



Q4FY20 - Profitability statement

		Standalone		Consolidated		
PARTICULARS ((₹ mln)	Q4FY19	Q4FY20	% change	Q4FY19	Q4FY20	% change
Total Revenue	853.54	634.31	-25.68%	860.01	642.54	-25.29%
Direct Cost	40.35	29.78		40.34	34.14	
Gross Profit	813.19	604.53	-25.66%	819.67	608.40	-25.78%
Gross Margin	95.27%	95.31%	+4bps	95.31%	94.69%	-62bps
Operating Cost						
Research and Development (R&D)	132.31	128.47		132.32	128.47	
Sales and Marketing (S&M)	193.12	234.67		198.11	238.58	
General Administration (G&A)	98.58	161.13		103.04	165.50	
Total Expenditure	424.01	524.27	-23.65%	433.46	532.55	-22.86%
EBITDA	389.18	80.26	-79.38%	386.21	75.85	-80.36%
EBITDA Margin	45.60%	12.65%	-3295bps	44.91%	11.80%	-3311bps
Depreciation	56.27	55.88		56.32	55.93	
EBIT	332.91	24.38	-92.68%	329.89	19.92	-93.96%
EBIT Margin	39.00%	3.84%	-3516bps	38.36%	3.10%	-3526bps
Other Income	84.80	81.12		85.15	82.42	
Profit Before Tax (PBT before exceptional items)	417.71	105.50	-74.74%	415.04	102.34	-75.34%
Exceptional Item	43.17	23.17		0.00	0.00	
Profit Before Tax (PBT after exceptional items)	374.54	82.33		415.04	102.34	
Тах	137.28	22.09		137.57	22.41	
Profit After Tax (PAT)	237.26	60.24	-74.61%	277.47	79.93	-71.19%
PAT Margin	27.80%	9.50%	-1830bps	32.26%	12.44%	-1982bps

NOTE: Certain figures have been re-grouped wherever necessary; Q4FY20 figures are low due to **COVID-19** impact

FY20 – Profitability statement

	Standalone			Consolidated		
PARTICULARS (₹ mln)	FY19	FY20	% change	FY19	FY20	% change
Total Revenue	3,129.03	2,834.04	-9.43%	3,149.26	2,861.38	-9.14%
Direct Cost	153.23	111.75		151.50	124.13	
Gross Profit	2,975.80	2,722.29	-8.52%	2,997.76	2,737.25	-8.69%
Gross Margin	95.10%	96.06%	+96bps	95.19%	95.66%	+47bps
Operating Cost						
Research and Development (R&D)	541.47	532.90		541.47	532.90	
Sales and Marketing (S&M)	670.42	714.69		690.49	731.17	
General Administration (G&A)	469.77	543.90		486.79	559.26	
Total Expenditure	1,681.66	1,791.49	-6.53%	1,718.75	1,823.33	-6.08%
EBITDA	1,294.14	930.80	-28.08%	1,279.01	913.92	-28.54%
EBITDA Margin	41.36%	32.84%	-852bps	40.61%	31.94%	-867bps
Depreciation	235.27	216.64		235.49	216.77	
EBIT	1,058.87	714.16	-32.55%	1,043.52	697.15	-33.19%
EBIT Margin	33.84%	25.20%	-864bps	33.14%	24.36%	-878bps
Other Income	325.00	313.41		326.67	315.96	
Profit Before Tax (PBT before exceptional items)	1,383.87	1,027.57	-25.75%	1,370.19	1,013.11	-26.06%
Exceptional Item	93.17	23.17		0.00	0.00	
Profit Before Tax (PBT after exceptional items)	1,290.70	1,004.40		1,370.19	1,013.11	
Тах	451.06	268.01		451.95	269.00	
Profit After Tax (PAT)	839.64	736.39	-12.30%	918.24	744.11	-18.96%
PAT Margin	26.83%	25.98%	-85bps	29.16%	26.01%	-315bps

NOTE: Certain figures have been re-grouped wherever necessary; Q4FY20 figures are low due to **COVID-19** impact

0/	Stand	alone	Consolidated	
n %	Q4FY19	Q4FY20	Q4FY19	Q4FY20
xpenses				
Direct Cost / Revenue	4.73%	4.69%	4.69%	5.31%
R&D / Revenue	15.50%	20.25%	15.39%	19.99%
S&M / Revenue	22.63%	37.00%	23.04%	37.13%
G&A / Revenue	11.55%	25.40%	11.98%	25.76%
otal Cost / Revenue	49.68%	82.65%	50.40%	82.88%
Margin				
Gross Margin	95.27%	95.31%	95.31%	94.69%
BITDA	45.60%	12.65%	44.91%	11.80%
BIT	39.00%	3.84%	38.36%	3.10%
PBT (Before Exceptional Item)	48.94%	16.63%	48.26%	15.93%
PBT (After Exceptional Item)	43.88%	12.98%	48.26%	15.93%
PAT	27.80%	9.50%	32.26%	12.44%

FY20 - Ratio analysis

Stand	alone	Consolidated	
FY19	FY20	FY19	FY20
4.90%	3.94%	4.81%	4.34%
17.30%	18.80%	17.19%	18.62%
21.43%	25.22%	21.93%	25.55%
15.01%	19.19%	15.46%	19.55%
53.74%	63.21%	54.58%	63.72%
95.10%	96.06%	95.19%	95.66%
41.36%	32.84%	40.61%	31.94%
33.84%	25.20%	33.14%	24.36%
44.23%	36.26%	43.51%	35.41%
41.25%	35.44%	43.51%	35.41%
26.83%	25.98%	29.16%	26.01%
	FY19 4.90% 17.30% 21.43% 15.01% 53.74% 95.10% 41.36% 33.84% 44.23% 41.25%	4.90%3.94%17.30%18.80%21.43%25.22%15.01%19.19%53.74%63.21%95.10%96.06%41.36%32.84%33.84%25.20%44.23%36.26%41.25%35.44%	FY19FY20FY194.90%3.94%4.81%17.30%18.80%17.19%21.43%25.22%21.93%15.01%19.19%15.46%53.74%63.21%54.58%95.10%96.06%95.19%41.36%32.84%40.61%33.84%25.20%33.14%44.23%36.26%43.51%41.25%35.44%43.51%

Consolidated Balance Sheet

QUITY AND LIABILITIES ([₹] mln)	31 Mar 2019	31 Mar 2020	ASSETS ([₹] mln)	31 Mar 2019	31 Mar 2020
Share Holder's Funds:		2020	Non-Current Assets:		
Equity Share Capital	705.63	642.03	Property, plant and equipment	1,570.04	1,485.09
			Capital work-in-progress	106.33	34.00
Share application money pending allotment	0.17	-	Intangible assets	77.08	99.81
	7 4 6 4 7 6		Non-current financial assets		
Reserves and Surplus	7,191.79	5,798.65	Investments in MF ,Tax-Free Bonds	296.23	353.32
Total Shareholder Funds	7,897.59	6,440.68	Loan and Security Deposits	3.75	3.81
Non-Current Liabilities			Bank Balances	4.04	3.91
Net employee defined benefit			Deferred tax assets (net)	86.69	25.86
liabilities	18.37	4.62	Other non current assets	46.06	173.24
Other Non Current Liabilities	19.53	19.63	Total Non-Current Assets	2,190.22	2,179.04
Total Non-Current Liabilities	37.90	24.25	Current assets:	F2 04	C2 40
	57.50	24.23	Inventories	53.94	62.40
Current Liabilities:			Investment in Mutual Fund	3,602.17	2,745.22
Trade and Other Payables	387.87	387.27	Trade and other receivables	1,250.52	1,131.62
Other Financial Liabilities	34.23	9.04	Bank Balances & Cash and Cash Equivalents	101.67	101.73
Other Current Liabilities	135.76	86.68	Investment in Fixed Deposit	1,247.33	698.52
Net employee defined benefit	04.00		Loan and security deposits	7.09	7.74
liabilities	21.22	3.94	Interest accrued on FDR and Tax-Free	30.59	15.26
Current tax liabilities (Net)	13.70	13.80	Bonds		
Total Current Liabilities	592.78	500.73	Other Current assets	44.74	24.13
			Total Current Assets	6,338.05	4,786.62
Total Equity & Liabilities	8,528.27	6,965.66	Total Assets	8,528.27	6,965.66

NOTE: Certain figures have been re-grouped wherever necessary

Standalone Balance Sheet

EQUITY AND LIABILITIES (₹ mln)	31 Mar 2019	31 Mar 2020	ASSETS (₹ mln)	31 Mar 2019	31 Mar 2020
Share Holder's Funds:			Non-Current Assets:		
Equity Share Capital	705.63	642.03	Property, plant and equipment	1,569.69	1,484.82
Share application money pending			Capital work-in-progress	106.33	34.00
allotment	0.17	0.00	Intangible assets	76.86	99.61
Reserves and Surplus	7,243.12	5,840.10	Non-current financial assets		
Total Shareholder Funds	7,948.92	6,482.13	Investments in MF & Tax-Free Bonds & Subsidiaries	406.53	453.96
Non-Current Liabilities	,	,	Loan and Security Deposits	3.75	3.81
Non-current Liabilities			Bank Balances	4.04	3.91
Net employee defined benefit liabilities	18.37	4.62	Deferred tax assets (net)	86.69	25.86
Other Non Current Liabilities	19.53	19.63	Other non current assets	46.06	173.24
Total Non-Current Liabilities	37.90	24.25	Total Non-Current Assets	2,299.95	2,279.21
			Current assets:		
Current Liabilities:			Inventories	41.41	62.19
Trade and Other Payables	384.83	383.60	Investment in Mutual Fund	3,602.17	2,745.22
Other Financial Liabilities	34.23	9.04	Trade and other receivables	1,248.55	1,132.26
Other Current Liabilities	131.49	83.79	Bank Balances & Cash and Cash Equivalents	51.74	36.58
Net employee defined benefit liabilities	21.12	3.94	Investment in Fixed Deposit	1,247.33	698.52
	12.02	12.02	Loan and security deposits	6.43	7.08
Current tax liabilities (Net)	13.03	13.03	Interest accrued on FDR and Tax-Free	30.60	15.30
Total Current Liabilities	584.70	493.40	Bonds Other Current accets		
Total Equity & Liabilities	8,571.52	6,999.78	Other Current assets	43.34	23.42
			Total Current Assets	6,271.57	4,720.57

Total Assets

NOTE: Certain figures have been re-grouped wherever necessary

6,999.78

8,571.52

Working capital analysis

6

Inventory

Davs

138

Receivable


Davs

At the end of March 2019

43

Payable

Davs



At the end of December 2019


At the end of March 2020



Receivable Days = [(Debtors/ Sales) X (366 days)] Inventory Days = [(Inventory/Sales) X (366 days)] Payable Days = [(Creditor/Sales) X (366 days)]

Calculation is based on net revenues before adjusting for sales incentives

Return ratio analysis



Company is continuously evaluating strategic inorganic opportunities to invest across the cybersecurity ecosystem
 Till such time the company invests its surplus cash in mutual funds, tax free-bonds and fixed deposits

RoCE = EBIT / Avg. Capital Employed (Equity + Debt) **Cash Adj. RoCE** = EBIT / Avg. Cash Adj. Capital Employed (Equity + Debt – Cash & Cash Equivalents)

ROE = PAT / Avg. Equity

* Calculated on trailing 12 months basis





Thank You

Chief Financial Officer

Mr. Nitin Kulkarni Nitin.Kulkarni@quickheal.co.in +91-20-66813232

Company Secretary

Mr. Srinivas Anasingaraju cs@quickheal.co.in +91-20-66813232

CIN No: L72200MH1995PLC091408 www.quickheal.co.in

Annexure

Products Sold in following countries

- Italy
- Nigeria
- UAE
- Kenya
- Philippines
- Colombia
- Sri Lanka
- Singapore
- Congo
- Bangladesh
- Thailand
- Peru
- Australia

- Mexico
- Hong Kong

- Venezuela
- USA

- Mauritius
- South Africa
- lordan
- Malaysia
- Gambia
- Guinea
- New Zealand
- Cambodia
- Ecuador

- Germany
 - Malta
 - Uganda
 - Iraq
 - El Salvador
 - Croatia
 - Nicaragua
 - Zambia
 - Poland

Mvanmar

- Honduras
- Rwanda

Chile

• South Korea

Saudi Arabia

Paraguay

• Turkey

Aruba

Ghana

Tanzania

Canada

Panama

- Netherlands

Sales & Support offices across India

- Chandigarh
- New Delhi
- laipur
- Lucknow
- Patna
- Guwahati
- Ahmedabad
- Indore
- Surat
- Nashik
- Nagpur
- Mumbai
- Pune

- Aurangabad
- Kolhapur
- Raipur
- Kolkata
- Bhubaneshwar
- Hyderabad
- Bangalore
- Chennai
- Kochi

